Investigators at Ileadbms Co. Ltd. have discovered a new cyclin-dependent kinase 12 (CDK12) and CDK13 inhibitor, IL6-110, which is being developed for the treatment of cancer.
Alterations in mitochondrial dynamics are hallmarks of Parkinson’s disease (PD) and other neurodegenerative disorders such as Alzheimer’s disease (AD).
Mutations in the gene encoding calpain-3, CAPN3, are causative for autosomal recessive limb-girdle muscular dystrophy-1 (LGMDR1), a type of muscular dystrophy characterized by muscle weakening around the shoulders and hips for which there is currently no treatment.
Advances in understanding the processes underlying brain neurodegeneration have allowed lots of new treatment and prevention strategies to begin to flourish. Several presentations at the 2024 Alzheimer’s & Parkinson’s Diseases Conference recently held in Lisbon reflect that eyes are now on some individuals who, despite showing pathological signs in their brains, stay cognitively healthy across several endogenous mechanisms of resilience.
In a new study, researchers from Harvard Medical School and Regulus Therapeutics Inc. further investigated the role of miR-155 in Alzheimer's disease (AD).
TET2 is a master epigenetic enzyme that converts 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC), reprograming tumor cells and causing them to enter a dormant state.
Hidradenitis suppurativa (HS) is an inflammatory skin disease with significant diagnostic delay. Type XXII collagen is a fibrillar collagen located in the skin epidermis. Reliable biomarkers to aid in the diagnosis of HS and monitor the severity of disease are needed.
The activation of the NLRP3 inflammasome exacerbates neuronal dysfunction in several neurological diseases such as Alzheimer’s and Parkinson’s diseases, as well as multiple sclerosis. Targeting NLRP3 is an approach to overcome brain inflammation, among others.
In allergic diseases, STAT6 is a critical transcription factor in the IL-4 and IL-13 signaling pathways and the key driver of Th2 inflammation. Because STAT6 functions through protein-protein and protein-DNA interactions, selectively and potently inhibiting STAT6 with traditional small-molecule inhibitors has been a challenge. However, it is well suited for a targeted protein degradation approach, whereby a binding event is adequate to direct degradation.
RSS
